医药稳健科研股策略:年化收益率（26.1%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 76.43%
- 年化收益率: 26.1%
- 基准收益率: 18.4%
- 阿尔法: 0.21
- 夏普比率: 0.91
- 最大回撤: 22.09%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2026-03-31 | 力生制药(002393.SZ) | 21.657896794798 | 24937 | 101 | 23.66 | 590009.42 | 49926.45/9.244% |
| 2026-03-31 | 通化东宝(600867.SH) | 9.0265914817798 | 62800 | 101 | 9.49 | 595972 | 29102.05/5.134% |
| 2026-03-31 | 浙江医药(600216.SH) | 13.994283947457 | 35490 | 251 | 16.07 | 570324.3 | 73667.16/14.833% |
| 2026-03-30 | 力生制药(002393.SZ) | 21.657896794798 | 25237 | 100 | 24.02 | 606192.74 | 59612.4/10.906% |
| 2026-03-30 | 通化东宝(600867.SH) | 9.0265914817798 | 63700 | 100 | 9.54 | 607698 | 32704.12/5.688% |
| 2026-03-30 | 浙江医药(600216.SH) | 13.957191691776 | 34990 | 250 | 16.6 | 580834 | 92471.86/18.935% |
| 2026-03-27 | 力生制药(002393.SZ) | 21.657896794798 | 25237 | 99 | 23.83 | 601397.71 | 54817.37/10.029% |
| 2026-03-27 | 通化东宝(600867.SH) | 9.0265914817798 | 63700 | 99 | 8.9 | 566930 | -8063.88/-1.402% |
| 2026-03-27 | 浙江医药(600216.SH) | 13.957191691776 | 34990 | 249 | 15.9 | 556341 | 67978.86/13.92% |
| 2026-03-26 | 力生制药(002393.SZ) | 21.657896794798 | 25237 | 98 | 23.43 | 591302.91 | 44722.57/8.182% |
交易详情
| 2026-03-31 | 通化东宝(600867.SH) | 卖 | -900 | 9.5 | -8550 | ¥13.55 | 426.07 |
| 2026-03-31 | 浙江医药(600216.SH) | 买 | 500 | 16.58 | 8290 | ¥5 | 0 |
| 2026-03-31 | 力生制药(002393.SZ) | 卖 | -300 | 23.81 | -7143 | ¥12.14 | 645.63 |
| 2026-03-24 | 力生制药(002393.SZ) | 卖 | -700 | 20.92 | -14644 | ¥19.64 | -516.53 |
| 2026-03-24 | 浙江医药(600216.SH) | 买 | 1200 | 14.98 | 17976 | ¥5.39 | 0 |
| 2026-03-17 | 通化东宝(600867.SH) | 卖 | -1000 | 9.12 | -9120 | ¥14.12 | 93.41 |
| 2026-03-17 | 力生制药(002393.SZ) | 买 | 100 | 22.26 | 2226 | ¥5 | 0 |
| 2026-03-17 | 浙江医药(600216.SH) | 买 | 1000 | 16.5 | 16500 | ¥5 | 0 |
| 2026-03-10 | 通化东宝(600867.SH) | 卖 | -100 | 8.96 | -896 | ¥5.9 | -6.66 |
| 2026-03-10 | 力生制药(002393.SZ) | 买 | 800 | 22.11 | 17688 | ¥5.31 | 0 |
